Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 2 47-2, 2003, Pages

  Luzi, Livio ^a,b   Perseghin, Gianluca ^a   Tambussi, Giuseppe ^a   Meneghini, Elena ^a   Scifo, Paola ^a   Pagliato, Emanuela ^a   Del Maschio, Alessandro ^a   Testolin, Giulio ^a   Lazzarin, Adriano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BASAL METABOLIC RATE; BODY FAT; CALORIMETRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; LIPODYSTROPHY; MALE; MUSCLE CELL; MUSCLE LEVEL; OBESITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REGRESSION ANALYSIS; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE;

EID: 0037303554     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00391.2001     Document Type: Article

References (44)

1. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, and Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031, 2002.
2. Brinkman K, Smeitink JA, Romijn JA, and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115, 1999.
3. Brunzell JD, Shankle SW, and Bethune JE. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann Intern Med 69: 501-516, 1968.
4. Capiluppi B, Ciuffreda D, Sciandra M, Marroni M, Tambussi G, and Lazzarin A. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. AIDS 14: 1861-1862, 2000.
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
6. Carr A, Samaras K, Chisholm DJ, and Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883, 1998.
7. Czaja AJ, Carpenter HA, Santrach PJ, and Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29: 198-206, 1998.
8. Deisenhammer F, Willeit J, Schmidauer C, Kiechl S, and Pohl P. Membranous lipodystrophy (Nasu-Hakola disease). Neruenarzt 64: 263-265, 1993.
9. Ducobu J and Payen MC. Lipids and AIDS. Rev Med Brux 21: 11-17, 2000.
10. Enzi G. Multiple symmetric lipomatosis: an updated clinical report. Medicine 63: 53-64, 1984.
11. Gan SK, Samaras K, Thompson C, Kraegen E, Carr A, Cooper D, and Chisholm D. Correlations between intramyocellular lipid, visceral fat and insulin sensitivity: a study of HIV positive subjects with and without peripheral lipodystrophy (Abstract). Diabetes 50: A315, 2001.
12. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, and Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105: 271-278, 2000.
13. Gnudi L, Shepherd PR, and Kahn BB. Over-expression of GLUT4 selectively in adipose tissue in transgenic mice:implication for nutrient partitioning. Proc Nutr Soc 55: 191-199, 1996.
14. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, and Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 284: 472-477, 2000.
15. Hajjar DP, Picart F, and Pomerantz KB. Molecular motions and thermotropic phase behavior of triacylglycerols and cholesteryl esters in herpesvirus-infected arterial smooth muscle cells: a deuterium nuclear magnetic resonance study. Biophys Chem 43: 255-263, 1992.
16. Harbour JR, Rosenthal P, and Smuckler EA. Ultrastructural abnormalities of the liver in total lipodystrophy. Hum Pathol 12: 856-862, 1981.
17. Hommes MJ, Romijn JA, Endert E, and Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 54: 311-315, 1991.
18. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, and Quon MJ. Quantitative Insulin Sensitivity Check Index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000.
19. Katz EB, Stenbit AE, Hatton K, De Pinho R, and Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT 4. Nature 377: 151-155, 1995.
20. Klein S, Jahoor F, Wolfe RR, and Stuart CA. Generalized lipodystrophy: in vivo evidence for hypermetabolism and insulin-resistant lipid, glucose, and amino acid kinetics. Metabolism 41: 893-896, 1992.
21. Kobberling J, Willms B, Kattermann R, and Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipoatrophic diabetes. Humangenetik 29: 111-120, 1975.
22. Korach M, Leclercq P, Peronnet F, and Leverve X. Metabolic response to a C-glucose load in human immunodeficiency virus patients before and after antiprotease therapy. Metabolism 51: 307-313, 2002.
23. Luzi L, Castellino P, and DeFronzo RA. Insulin and hyperaminoacidemia regulate by a different mechanism leucine turnover and oxidation in obesity. Am J Physiol Endocrinol Metab 270: E273-E281, 1996.
24. Luzi L, Dozio N, Battezzati A, Perseghin G, Sarugeri E, Terruzzi I, and Spotti D. Anomalous leucine metabolism in total lipoathrophic diabetes: a possible mechanism of muscle mass hypertrophy. Acta Diabetol 29: 86-93, 1992.
25. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, and Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13: 735-737, 1999.
26. McGarry JD. Glucose-fatty acid interactions in health, and disease. Am J Clin Nutr 67: 500S-504S, 1998.
27. Murata H, Hruz PW, and Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. JBiol Chem 275: 20251-20254, 2000.
28. Pearce PH, Johnsen RD, Wysocki SJ, and Kakulas BA. Muscle lipids in Duchenne muscular dystrophy. Aust J Exp Biol Med Sci 59: 77-90, 1981.
29. Pernerstorfer-Schoen H, Schindler K, Parschalk B, Schindl A, Thoeny-Lampert S, Wunderer K, Elmadfa I, Tschachler E, and Jilma B. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 13: 2389-2396, 1999.
30. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, and Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans. A 1H-13C NMR spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48: 1600-1606, 1999.
31. Perseghin G, Scifo P, Pagliato E, Battezzati A, Soldini L, Benedini S, Testolin G, Del Maschio A, and Luzi L. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. J Clin Endocrinol Metab 86: 3188-3196, 2001.
32. Pihlajamaki J, Karjalainen L, Karhapaa P, Vauhkonen I, and Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 20: 164-170, 2000.
33. Polo M, Galli M, Scientmark T, and Walli R. Proposal for a clinical and metabolic classification of metabolic and hormone abnormalities under HAART. In: Int Workshop 2nd on HIV-related Lipodystrophy, Marrakesh, Morocco, 2000, p. 57-58.
34. Renard E, Fabre J, Paris F, Reynes J, and Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51: 223-230, 1999.
35. Ruderman NB and Dean D. Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. J Basic Clin Physiol Pharmacol 9: 295-308, 1998.
36. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, and Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-1667, 1999.
37. Sheehan LA and Macallan DC. Determinants of energy intake and energy expenditure in HIV and AIDS. Nutrition 16: 101-106, 2000.
38. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, and Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 13: 1351-1357, 1999.
39. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296, 1997.
40. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, and Stein DT. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol Endocrinol Metab 276: E977-E989, 1999.
41. Tsu-Shuen Tsao, Stenbit AE, J Li, Houseknecht KL, Zierath JR, Katz EB, and Charron MJ. Muscle-specific transgenic complementation of GLUT4-deficient mice. J Clin Invest 100: 671-677, 1997.
42. Ursich MJ, Fukui RT, Galvao MS, Marcondes JA, Santomauro AT, Silva ME, Rocha DM, and Wajchenberg BL. Insulin resistance in limb, and trunk partial lipodystrophy (type 2 Kobberling-Dunnigan syndrome). Metabolism 46: 159-163, 1997.
43. Walli R, Michl GM, Muhlbayer D, Brinkmann L, and Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 199: 253-262, 2000.
44. Wanke C, Gerrior J, Kantaros J, Coakley E, and Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099-2103, 1999.